<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72353">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02116842</url>
  </required_header>
  <id_info>
    <org_study_id>AN10/9307</org_study_id>
    <secondary_id>2010-020020-21</secondary_id>
    <secondary_id>11730</secondary_id>
    <nct_id>NCT02116842</nct_id>
  </id_info>
  <brief_title>Minimum Effective Dose (MED) &amp; Epidural Bupivacaine</brief_title>
  <official_title>Comparison of the ED95 Dose of 0.075% and 0.1% Bupivacaine for Labour Analgesia in Primigravida.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Academic Anaesthesia (NIAA), UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Obstetric Anaethetists' Association (OAA), UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Local anaesthetics are highly toxic drugs. They can cause toxicity by an absolute overdose,
      accidental injection in a blood vessel or slow absorption from the area of injection. The
      risk of toxicity when performing regional anaesthesia can be reduced significantly by
      injecting the optimal dose of local anaesthetic at the correct site.

      To date most of the local anaesthetic dose finding studies for epidural labour analgesia has
      focused on ED50 ( the dose effective in 50% of patients). The purpose of this research study
      is to find out the ED95 dose (the dose effective in 95% of patients) of local anaesthetic
      for epidural analgesia in labour.

      The dose determined from this research trial will guide the anaesthetists to the optimal
      starting dose of the local anaesthetics for epidural analgesia in labour. This would lead to
      decreased chances of toxicity and will improve patient safety.

      We aim to recruit a total of 100 pregnant patients in early labour (cervical dilatation ≤ 5
      cm) requesting epidural analgesia to answer the research question based on the continual
      reassessment method. Patients will be recruited according to well-defined criteria. They
      will be fully informed about the study and have the choice of not participating or opting
      out at any time during the study. It is not going to affect the kind of treatment they
      receive. The experts in the field with full safety precautions will perform this study at St
      James' Hospitals, Leeds.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effective dose in 95% of patients (ED95) dose of bupivacaine for a primigravida in early labour.</measure>
    <time_frame>up to 30 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To find out the ED95 dose of bupivacaine 0.075% and 0.1% for epidural analgesia for a primigravida in early labour .</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pregnancy</condition>
  <condition>Labour</condition>
  <condition>Primigravida Labour</condition>
  <condition>Epidural Block</condition>
  <arm_group>
    <arm_group_label>0.075% bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consenting patients randomised to receive 0.075% bupivacaine and 40 µg fentanyl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consenting patients randomised to receive 0.1% bupivacaine and 40 µg fentanyl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% bupivacaine</intervention_name>
    <description>Epidural block in early labour.</description>
    <arm_group_label>0.1% bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.075% bupivacaine</intervention_name>
    <description>Epidural block in early labour.</description>
    <arm_group_label>0.075% bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 µg fentanyl</intervention_name>
    <description>Given with different doses of bupivacaine in epidural block.</description>
    <arm_group_label>0.075% bupivacaine</arm_group_label>
    <arm_group_label>0.1% bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anaesthesiologists (ASA) 1-3 patients

          -  Primigravida (1st pregnancy) patients requesting epidural analgesia in early labour
             (≤ 5 cm cervical dilatation.

        Exclusion Criteria:

          -  Primigravida (1st pregnancy) patients requesting epidural analgesia in late labour (&gt;
             5 cm cervical dilatation)

          -  Multigravida patients ( ≥ 2nd pregnancy)

          -  ASA &gt; 3

          -  Allergy to Bupivacaine

          -  Unable to give written informed consent

          -  BMI &gt;35

          -  Abnormal blood coagulation profile

          -  Patients taking any medication that are indicated in the Summary of Product
             Characteristics (SPC) as not recommended
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Philip M Hopkins</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leeds</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neville Young</last_name>
    <phone>44 113 392 6459</phone>
    <email>neville.young@leedsth.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leeds Sponsor Office Quality Assurance Department</last_name>
    <phone>44 113 392 2878</phone>
    <email>r&amp;d@leedsth.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Sandeep Varma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Neville Young</investigator_full_name>
    <investigator_title>Sponsor Quality Assurance Manager</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
